Barclays PLC filed Amendment No. 1 to a Schedule 13G with the SEC on November 6, 2026, disclosing a beneficial ownership position in the common stock of Cartesian Therapeutics Inc as of September 30, 2026.

Key Highlights

  • Filer: Barclays PLC, organized in the United Kingdom and classified as a holding company (HC), filed the amended schedule.
  • Aggregate beneficial ownership: 7,233 shares of Cartesian Therapeutics Inc common stock, representing 0.02% of the class, according to the filing.
  • Shared voting power: 19,462 shares carry shared voting power, with zero shares held with sole voting power.
  • Shared dispositive power: 19,462 shares carry shared dispositive power, with zero shares held with sole dispositive power.
  • Relevant subsidiaries: The filing identifies Barclays Bank PLC, Barclays Capital Inc, and Barclays Capital Securities Ltd as the subsidiaries that acquired the reported securities.
  • Event date: The date of the event requiring this filing is stated as September 30, 2026.

Barclays PLC Discloses Sub-1% Stake in Cartesian Therapeutics via Amended Schedule 13G

According to the filing, Barclays PLC submitted Amendment No. 1 to Schedule 13G covering shares of Cartesian Therapeutics Inc (CUSIP 816212302) common stock. The event triggering the amendment occurred on September 30, 2026, and the statement was signed on November 6, 2026 by Ramya Rao, identified as a Director of Barclays PLC.

The filing reports that Barclays PLC beneficially owns 7,233 shares, equating to 0.02% of the outstanding class. However, the shared voting and shared dispositive power figures each stand at 19,462 shares, a figure that the filing attributes to positions held across the identified subsidiaries: Barclays Bank PLC, Barclays Capital Inc, and Barclays Capital Securities Ltd. The filing does not provide an explicit reconciliation of the difference between the 19,462 shared-power figure and the 7,233 aggregate beneficial ownership figure.

The filing certifies, as required under Schedule 13G, that the securities "were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer." Item 5 of the filing confirms ownership of 5 percent or less of the class, and Item 6 states that ownership on behalf of another person is not applicable.

What Was Disclosed

Barclays PLC disclosed an amended Schedule 13G position in Cartesian Therapeutics Inc common stock, reporting aggregate beneficial ownership of 7,233 shares (0.02% of class) with shared voting and dispositive power each covering 19,462 shares, through subsidiaries including Barclays Bank PLC, Barclays Capital Inc, and Barclays Capital Securities Ltd.